Muropeptides are breakdown products of peptidoglycan (PGN) of Gram-negative and Gram-positive bacteria. They are released during bacterial growth and division, as part of the host response by lysozyme and amidases, or upon antibiotic treatment. After phagocytosis of bacteria or bacterial breakdown products by host immune cells, the muropeptides trigger intracellular signaling cascades, leading to altered gene expression and activation of the immune response. Numerous muropeptides and derivatives have been synthesized chemically to characterize their immunostimulatory effects and adjuvant activity. Muramyl dipeptide, a natural partial structure of PGN, is the minimal structure with adjuvant activity. This review discusses the structure and occurrence of muropeptides and gives a broad overview of their inflammatory and adjuvant activity and the possible involvement of receptors in these responses.
Seydel U., Schromm AB, Blunck R., Brandenburg K.Chemical structure, molecular conformation, and bioactivity of endotoxins . Chem Immunol2000; 74: 5—24.
2.
Aasjord P., Grov A.Immunoperoxidase and electron microscopy studies of staphylococcal lipoteichoic acid. Acta Pathol Microbiol Scand [B] 1980 ; 88: 47—52.
3.
Morath S., Stadelmaier A., Geyer A., Schmidt RR, Hartung T.Synthetic lipoteichoic acid from Staphylococcus aureus is a potent stimulus of cytokine release. J Exp Med2002; 195: 1635—1640.
4.
Morath S., Geyer A., Spreitzer I., Hermann C., Hartung T.Structural decomposition and heterogeneity of commercial lipoteichoic acid preparations. Infect Immun2002; 70::938—944.
5.
Dmitriev BA, Toukach FV, Holst O., Rietschel ET, Ehlers S.Tertiary structure of Staphylococcus aureus cell wall murein. J Bacteriol2004; 186::7141—7148.
6.
Vollmer W., Holtje JVThe architecture of the murein (peptidoglycan) in Gram-negative bacteria: vertical scaffold or horizontal layer(s)?J Bacteriol2004; 186: 5978—5987.
7.
Ellouz F., Adam A., Ciorbaru R., Lederer E.Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun1974 ; 59: 1317—1325.
8.
Beutler B. Inferences, questions and possibilities inToll-like receptor signalling . Nature2004; 430: 257—263.
9.
Zhang D., Zhang G., Hayden MS et al. A Toll-like receptor that prevents infection by uropathogenic bacteria. Science2004; 303: 1522—1526.
10.
Tabeta K., Georgel P., Janssen E. et al. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci USA2004; 101: 3516—3521.
11.
Yarovinsky F., Zhang D., Andersen JF et al. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science2005; 308: 1626—1629.
12.
Medzhitov R.Toll-like receptors and innate immunity. Nat Rev Immunol2001; 1::135—145.
13.
Dunne A., Ejdeback M., Ludidi PL, O'Neill LA, Gay NJStructural complementarity of Toll/interleukin-1 receptor domains in Toll-like receptors and the adaptors Mal and MyD88. J Biol Chem2003; 278: 41443 -41451.
Poltorak A. , He X., Smirnova I. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science1998; 282: 2085—2088.
16.
Hoshino K., Takeuchi O., Kawai T. et al. Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol1999; 162: 3749—3752.
17.
Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JCCD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science1990; 249: 1431—1433.
18.
Beutler B., Rietschel ETInnate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol2003; 3: 169—176.
19.
Shimazu R., Akashi S., Ogata H. et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med1999; 189: 1777—1782.
20.
Schromm AB, Brandenburg K., Loppnow H. et al. Biological activities of lipopolysaccharides are determined by the shape of their lipid A portion. Eur J Biochem2000; 267: 2008—2013.
21.
Takeuchi O. , Hoshino K., Kawai T. et al. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components . Immunity1999; 11: 443—451.
22.
Yang S., Tamai R., Akashi S. et al. Synergistic effect of muramyldipeptide with lipopolysaccharide or lipoteichoic acid to induce inflammatory cytokines in human monocytic cells in culture. Infect Immun2001; 69: 2045—2053.
23.
Uehara A., Sugawara S., Takada H.Priming of human oral epithelial cells by interferon-gamma to secrete cytokines in response to lipopolysaccharides, lipoteichoic acids and peptidoglycans . J Med Microbiol2002; 51: 626—634.
24.
Lehner MD, Morath S., Michelsen KS, Schumann RR, Hartung T.Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like receptors independent of paracrine mediators . J Immunol2001; 166: 5161—5167.
25.
Opitz B., Schroder NW, Spreitzer I. et al. Toll-like receptor-2 mediates Treponema glycolipid and lipoteichoic acid-induced NF-kappaB translocation. J Biol Chem2001; 276::22041—22047.
26.
Travassos LH , Girardin SE, Philpott DJ et al. Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition. EMBO Report2004; 5: 1000—1006.
27.
Deininger S. , Stadelmaier A., Von Aulock S, Morath S., Schmidt RR, Hartung T.Definition of structural prerequisites for lipoteichoic acid-inducible cytokine induction by synthetic derivatives. J Immunol2003; 170: 4134—4138.
28.
Sugiyama A. , Arakaki R., Ohnishi T., Arakaki N., Daikuhara Y., Takada H.Lipoteichoic acid and interleukin 1 stimulate synergistically production of hepatocyte growth factor (scatter factor) in human gingival fibroblasts in culture. Infect Immun1996; 64::1426—1431.
29.
Gao JJ, Xue Q., Zuvanich EG, Haghi KR, Morrison DCCommercial preparations of lipoteichoic acid contain endotoxin that contributes to activation of mouse macrophages in vitro. Infect Immun2001; 69: 751—757.
30.
Hemmi H., Takeuchi O., Kawai T. et al. A Toll-like receptor recognizes bacterial DNA. Nature2000; 408: 740—745.
31.
Ahmad-Nejad P., Hacker H., Rutz M., Bauer S., Vabulas RM, Wagner H.Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol2002; 32: 1958—1968.
32.
Latz E., Schoenemeyer A., Visintin A. et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol2004; 5: 190—198.
33.
Wang JE, Jorgensen PF, Almlof M. et al. Peptidoglycan and lipoteichoic acid from Staphylococcus aureus induce tumor necrosis factor alpha, interleukin 6 (IL-6), and IL-10 production in both T cells and monocytes in a human whole blood model. Infect Immun2000; 68: 3965—3970.
34.
Thiemermann C.Interactions between lipoteichoic acid and peptidoglycan from Staphylococcus aureus: a structural and functional analysis . Microbes Infect2002; 4: 927—935.
35.
Dziarski R.Recognition of bacterial peptidoglycan by the innate immune system. Cell Mol Life Sci2003; 60: 1793—1804.
36.
Xu Z., Dziarski R., Wang Q., Swartz K., Sakamoto KM, Gupta D.Bacterial peptidoglycan-induced TNF-alpha transcription is mediated through the transcription factors Egr-1, Elk-1, and NF-kappaB. J Immunol2001; 167::6975—6982.
37.
Yoshimura A., Lien E., Ingalls RR, Tuomanen E., Dziarski R., Golenbock D.Recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol1999; 163: 1—5.
38.
Schwandner R., Dziarski R., Wesche H., Rothe M., Kirschning CJPeptidoglycan- and lipoteichoic acid-induced cell activation is mediated by Toll-like receptor 2. J Biol Chem1999; 274: 17406—17409.
39.
Mitsuzawa H. , Wada I., Sano H. et al. Extracellular Toll-like receptor 2 region containing Ser40—Ile64 but not Cys30—Ser39 is critical for the recognition of Staphylococcus aureus peptidoglycan. J Biol Chem2001; 276: 41350—41356.
40.
Kyburz D., Rethage J., Seibl R. et al. Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by Toll-like receptor signaling. Arthritis Rheum2003; 48: 642—650.
41.
Dziarski R. , Gupta D.Staphylococcus aureus peptidoglycan is a Toll-like receptor 2 activator: a re-evaluation. Infect Immun2005; 73: 5212—5216.
42.
Hoebe K., Georgel P., Rutschmann S. et al. CD36 is a sensor of diacylglycerides. Nature2005; 433: 523—527.
43.
Chamaillard M., Girardin SE, Viala J., Philpott DJNods, Nalps and Naip: intracellular regulators of bacterial-induced inflammation. Cell Microbiol2003; 5: 581—592.
44.
Chamaillard M., Hashimoto M., Horie Y. et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol2003; 4: 702—707.
45.
Girardin SE , Boneca IG, Viala J. et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem2003; 278: 8869—8872.
46.
Schleifer KH , Kandler O.Peptidoglycan types of bacterial cell walls and their taxonomic implications. Bacteriol Rev1972; 36: 407—477.
47.
Holtje JVGrowth of the stress-bearing and shape-maintaining murein sacculus of Escherichia coli. Microbiol Mol Biol Rev1998; 62: 181—203.
48.
Navarre WW, Schneewind O.Surface proteins of Gram-positive bacteria and mechanisms of their targeting to the cell wall envelope. Microbiol Mol Biol Rev1999; 63: 174—229.
49.
Severin A., Tomasz A.Naturally occurring peptidoglycan variants of Streptococcus pneumoniae. J Bacteriol1996; 178: 168—174.
Harz H., Burgdorf K., Höltje J-V.Isolation and separation of the glycan strands from murein of Escherichia coli by reversed-phase high-performance liquid chromatography. Anal Biochem1990; 190: 120—128.
52.
Vermeulen MW , Gray GRProcessing of Bacillus subtilis peptidoglycan by a mouse macrophage cell line. Infect Immun1984; 46: 476—483.
53.
Kerr DE, Plaut K., Bramley AJ et al. Lysostaphin expression in mammary glands confers protection against staphylococcal infection in transgenic mice. Nat Biotechnol2001; 19: 66—70.
54.
Horsburgh GJ , Atrih A., Williamson MP, Foster SJLytG of Bacillus subtilis is a novel peptidoglycan hydrolase: the major active glucosaminidase. Biochemistry2003; 42::257—264.
55.
Boneca IGThe role of peptidoglycan in pathogenesis. Curr Opin Microbiol2005; 8: 46—53.
56.
Wang ZM, Li X., Cocklin RR et al. Human peptidoglycan recognition protein-L is an N-acetylmuramoyl-L-alanine amidase. J Biol Chem2003; 278: 49044—49052.
57.
McLaughlan AM, Foster SJMolecular characterization of an autolytic amidase of Listeria monocytogenes EGD. Microbiology1998; 144: 1359—1367.
58.
Pappenheimer JR, Koski G., Fencl V., Karnovsky ML, Krueger J.Extraction of sleep-promoting factor S from cerebrospinal fluid and from brains of sleep-deprived animals. J Neurophysiol1975; 38: 1299—1311.
59.
Krueger JM, Pappenheimer JR, Karnovsky MLThe composition of sleep-promoting factor isolated from human urine. J Biol Chem1982; 257: 1664—1669.
60.
Martin SA, Karnovsky ML, Krueger JM, Pappenheimer JR, Biemann K.Peptidoglycans as promoters of slow-wave sleep. I. Structure of the sleep-promoting factor isolated from human urine. J Biol Chem1984; 259: 12652—12658.
61.
Krueger JM, Karnovsky ML, Martin SA, Pappenheimer JR, Walter J., Biemann K.Peptidoglycans as promoters of slow-wave sleep. II. Somnogenic and pyrogenic activities of some naturally occurring muramyl peptides; correlations with mass spectrometric structure determination. J Biol Chem1984; 259: 12659—12662.
62.
Fox A., Schwab JH, Cochran T.Muramic acid detection in mammalian tissues by gas-liquid chromatography-mass spectrometry. Infect Immun1980; 29: 526—531.
63.
Kozar MP, Krahmer MT, Fox A., Gray BMFailure To detect muramic acid in normal rat tissues but detection in cerebrospinal fluids from patients with pneumococcal meningitis. Infect Immun2000; 68:4688—4698.
64.
Sen Z., Karnovsky MLQualitative detection of muramic acid in normal mammalian tissues. Infect Immun1984; 43: 937—941.
65.
Christensson B., Gilbart J., Fox A., Morgan SLMass spectrometric quantitation of muramic acid, a bacterial cell wall component, in septic synovial fluids. Arthritis Rheum1989; 32: 1268—1272.
66.
Lehtonen L. , Kortekangas P., Oksman P., Eerola E., Aro H., Toivanen A.Synovial fluid muramic acid in acute inflammatory arthritis. Br J Rheumatol1994; 33: 1127—1130.
67.
Bal K., Larsson L.New and simple procedure for the determination of muramic acid in chemically complex environments by gas chromatography-ion trap tandem mass spectrometry . J Chromatogr B Biomed Sci Appl2000; 738: 57—65.
68.
Vavricka SR , Musch MW, Chang JE et al. hPepT1 transports muramyl dipeptide, activating NF-kappaB and stimulating IL-8 secretion in human colonic Caco2/bbe cells. Gastroenterology2004; 127::1401—1409.
69.
Tomasic J., Ladesic B., Valinger Z., Hrsak I.The metabolic fate of 14C-labeled peptidoglycan monomer in mice. I. Identification of the monomer and the corresponding pentapeptide in urine. Biochim Biophys Acta1980; 629:: 77—82.
70.
Yapo A., Petit JF, Lederer E., Parant M., Parant F., Chedid L.Fate of two 14C-labelled muramyl peptides: Ac-Mur-L-Ala-gamma-D-Glu-meso-A2pm and Ac-Mur-L-Ala-gamma-D-Glu-meso-A2pm-D-Ala-D-Ala in mice. Evaluation of their ability to increase non specific resistance to Klebsiella infection . Int J Immunopharmacol1982; 4: 143—149.
71.
Fosset S., Fromentin G., Rampin O., Lang V., Mathieu F., Tome D.Pharmacokinetics and feeding responses to muramyl dipeptide in rats. Physiol Behav2003; 79: 173—182.
72.
Fox A., Fox K.Rapid elimination of a synthetic adjuvant peptide from the circulation after systemic administration and absence of detectable natural muramyl peptides in normal serum at current analytical limits. Infect Immun1991; 59: 1202—1205.
73.
Dzierzbicka K., Kolodziejczyk AMMuramyl peptides — synthesis and biological activity. Polish J Chem2003; 77: 373—395.
74.
Dzierzbicka K., Kolodziejczyk AMSynthesis and antitumor activity of conjugates of muramyldipeptide or normuramyldipeptide with hydroxyacridine/acridone derivatives . J Med Chem2003; 46: 183—189.
75.
Wolfert MA, Murray TF, Boons GJ, Moore JNThe origin of the synergistic effect of muramyldipeptide with endotoxin and peptidoglycan. J Biol Chem2002; 277: 39179—39186.
76.
Dinarello CA, Krueger JMInduction of interleukin 1 by synthetic and naturally occurring muramyl peptides . Fed Proc1986; 45: 2545—2548.
77.
Safavi KE, Nichols FCEffects of a bacterial cell wall fragment on monocyte inflammatory function . J Endod2000; 26: 153—155.
78.
Martinon F., Burns K., Tschopp J.The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell2002; 10: 417—426.
79.
Martinon F. , Agostini L., Meylan E., Tschopp J.Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr Biol2004; 14: 1929—1934.
80.
Wang JE, Jorgensen PF, Ellingsen EA et al. Peptidoglycan primes for LPS-induced release of proinflammatory cytokines in whole human blood. Shock2001 ; 16: 178—182.
81.
Traub S., Kubasch N., Morath S. et al. Structural requirements of synthetic muropeptides to synergize with lipopolysaccharide in cytokine induction. J Biol Chem2004; 279: 8694—8700.
82.
Nagao S., Akagawa KS, Yamada K., Yagawa K., Tokunaga T., Kotani S.Lack of response of murine peritoneal macrophages to in vitro activation by muramyl dipeptide (MDP). I. Macrophage activation by MDP is species dependent . Microbiol Immunol1990; 34: 323—335.
83.
Le Contel C, Temime N., Charron DJ, Parant MAModulation of lipopolysaccharide-induced cytokine gene expression in mouse bone marrow-derived macrophages by muramyl dipeptide . J Immunol1993; 150: 4541.
84.
Srividya S. , Roy RP, Basu SK, Mukhopadhyay A.Scavenger receptor-mediated delivery of muramyl dipeptide activates antitumor efficacy of macrophages by enhanced secretion of tumor-suppressive cytokines. J Leukoc Biol2000; 67: 683—690.
85.
Parant M., Parant F., Vinit MA, Jupin C., Noso Y., Chedid L.Priming effect of muramyl peptides for induction by lipopolysaccharide of tumor necrosis factor production in mice. J Leukoc Biol1990; 47: 164—169.
86.
Baschang G.Muramylpeptides and lipopeptides: studies towards immunostimulants. Tetrahedron1989; 45::6331—6360.
87.
Mukherjee K. , Parashuraman S., Krishnamurthy G. et al. Diverting intracellular trafficking of Salmonella to the lysosome through activation of the late endocytic Rab7 by intracellular delivery of muramyl dipeptide. J Cell Sci2002; 115: 3693—3701.
88.
Chedid L., Parant M., Parant F., Lefrancher P., Choay J., Lederer E.Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. Proc Natl Acad Sci USA1977; 74: 2089—2093.
89.
Fraser-Smith EB, Matthews TRProtective effect of muramyl dipeptide analogs against infections of Pseudomonas aeruginosa or Candida albicans in mice. Infect Immun1981; 34: 676—683.
90.
Sarkar K., Das PKProtective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines. J Immunol1997; 158: 5357—5365.
91.
Johannsen L. , Obal Jr F., Kapas L., Kovalzon V., Krueger JMSomnogenic activity of muramyl peptide-derived immune adjuvants. Int J Immunopharmacol1994 ; 16: 109—116.
92.
Krueger JM, Majde JAMicrobial products and cytokines in sleep and fever regulation. Crit Rev Immunol1994; 14: 355—379.
93.
Obal Jr F., Krueger JMBiochemical regulation of non-rapid-eye-movement sleep. Front Biosci2003; 8::d520—550.
94.
Chen L., Taishi P., Majde JA, Peterfi Z., Obal Jr F., Krueger JMThe role of nitric oxide synthases in the sleep responses to tumor necrosis factor-alpha. Brain Behav Immun2004; 18: 390—398.
95.
Nelson EA, Wong Y., Yu LM, Fok TF, Li K.Effects of hyperthermia and muramyl dipeptide on IL-1beta, IL-6, and mortality in a neonatal rat model. Pediatr Res2002; 52: 886—891.
96.
Plata-Salaman CR1998 Curt P. Richter Award. Brain mechanisms in cytokine-induced anorexia. Psychoneuroendocrinology1999; 24: 25—41.
97.
Langhans W.Bacterial products and the control of ingestive behavior: clinical implications. Nutrition1996; 12: 303—315.
98.
Gayle D., Ilyin SE, Flynn MC, Plata-Salaman CRLipopolysaccharide (LPS)- and muramyl dipeptide (MDP)-induced anorexia during refeeding following acute fasting: characterization of brain cytokine and neuropeptide systems mRNAs. Brain Res1998 ; 795: 77—86.
99.
Porter MH, Hrupka BJ, Altreuther G., Arnold M., Langhans W.Inhibition of TNF-alpha production contributes to the attenuation of LPS-induced hypophagia by pentoxifylline. Am J Physiol2000; 279: R2113—2120.
100.
von Meyenburg C., Hrupka BH, Arsenijevic D., Schwartz GJ, Landmann R., Langhans W.Role for CD14, TLR2, and TLR4 in bacterial product-induced anorexia. Am J Physiol2004 ; 287: R298—305.
101.
Burroughs M., Rozdzinski E., Geelen S., Tuomanen E.A structure-activity relationship for induction of meningeal inflammation by muramyl peptides. J Clin Invest1993; 92: 297—302.
102.
Langford MP , Chen D., Welbourne TC, Redens TB, Ganley JPStereo-isomer specific induction of renal cell apoptosis by synthetic muramyl dipeptide (N-acetylmuramyl-L-alanyl-D-isoglutamine) . Mol Cell Biochem2002; 236: 63—73.
103.
Chen D., Duggan C., Reden TB, Kooragayala LM, Texada DE, Langford MPCalreticulin is a binding protein for muramyl dipeptide and peptidoglycan in RK13 cells. Biochemistry2004; 43: 11796—11801.
104.
Chen D., Texada DE, Duggan C. et al. Surface calreticulin mediates muramyl dipeptide induced apoptosis in RK13 cells. J Biol Chem2005; 280: 22425—22436.
105.
O'Reilly T. , Zak O.Enhancement of the effectiveness of antimicrobial therapy by muramyl peptide immunomodulators. Clin Infect Dis1992; 14: 1100—1109.
Darcissac EC, Bahr GM, Parant MA, Chedid LA, Riveau GJSelective induction of CD11a,b,c/CD18 and CD54 expression at the cell surface of human leukocytes by muramyl peptides . Cell Immunol1996; 169: 294—301 .
108.
Heinzelmann M., Polk Jr HC, Chernobelsky A., Stites TP, Gordon LEEndotoxin and muramyl dipeptide modulate surface receptor expression on human mononuclear cells . Immunopharmacology2000; 48: 117—128.
109.
Leclerc C. , Juy D., Bourgeois E., Chedid L.In vivo regulation of humoral and cellular immune responses of mice by a synthetic adjuvant, N-acetyl-muramyl-L-alanyl-D-isoglutamine, muramyl dipeptide for MDP. Cell Immunol1979 ; 45: 199—206.
110.
Dreesman GR , Sanchez Y., Ionescu-Matiu I. et al. Antibody to hepatitis B surface antigen after a single inoculation of uncoupled synthetic HBsAg peptides. Nature1982; 295: 158—160.
111.
Morisaki I. , Michalek SM, Harmon CC, Torii M., Hamada S., McGhee JREffective immunity to dental caries: enhancement of salivary anti-Streptococcus mutans antibody responses with oral adjuvants . Infect Immun1983; 40: 577—591.
112.
Masek K., Zaoral M., Jezek J., Straka R.Immunoadjuvant activity of synthetic N-acetyl muramyl dipeptide. Experientia1978; 34: 1363—1364.
113.
Saiki I., Fidler IJSynergistic activation by recombinant mouse interferon-gamma and muramyl dipeptide of tumoricidal properties in mouse macrophages. J Immunol1985; 135: 684—688.
114.
Souvannavong V., Brown S., Adam A.Muramyl dipeptide (MDP) synergizes with interleukin 2 and interleukin 4 to stimulate, respectively, the differentiation and proliferation of B cells. Cell Immunol1990; 126: 106—116.
115.
Takada H.Enhancement of endotoxin activity by muramyldipeptide. J Endotoxin Res2002; 8: 337—342.
116.
Takada H., Galanos C.Enhancement of endotoxin lethality and generation of anaphylactoid reactions by lipopolysaccharides in muramyl-dipeptide-treated mice. Infect Immun1987; 55: 409—413.
117.
Bloksma N., Hofhuis FM, Willers JMMuramyl dipeptide is a powerful potentiator of the antitumor action of various tumornecrotizing agents. Cancer Immunol Immunother1984; 17: 154—159.
118.
Takada H., Hirai H., Fujiwara T., Koga T., Ogawa T., Hamada S.Bacteroides lipopolysaccharides (LPS) induce anaphylactoid and lethal reactions in LPS-responsive and -nonresponsive mice primed with muramyl dipeptide. J Infect Dis1990; 162: 428—434.
119.
Takada H., Kawabata Y., Kawata S., Kusumoto S.Structural characteristics of peptidoglycan fragments required to prime mice for induction of anaphylactoid reactions by lipopolysaccharides. Infect Immun1996; 64: 657—659.
120.
Kobayashi KS, Chamaillard M., Ogura Y. et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science2005; 307: 731—734.
121.
Endo Y., Shibazaki M., Nakamura M., Takada H.Contrasting effects of lipopolysaccharides (endotoxins) from oral black-pigmented bacteria and Enterobacteriaceae on platelets, a major source of serotonin, and on histamine-forming enzyme in mice. J Infect Dis1997; 175::1404—1412.
122.
Kawabata Y. , Yang TS, Yokochi TT et al. Complement system is involved in anaphylactoid reaction induced by lipopolysaccharides in muramyldipeptide-treated mice. Shock2000; 14: 572—577.
123.
Ohba M., Shibazaki M., Sasano T., Inoue M., Takada H., Endo Y.Platelet responses and anaphylaxis-like shock induced in mice by intravenous injection of whole cells of oral streptococci. Oral Microbiol Immunol2004; 19: 26—30.
124.
Jorgensen PF, Wang JE, Almlof M. et al. Peptidoglycan and lipoteichoic acid modify monocyte phenotype in human whole blood. Clin Diagn Lab Immunol2001; 8: 515—521.
125.
Tsuchida K. , Takemoto Y., Yamagami S. et al. Detection of peptidoglycan and endotoxin in dialysate, using silkworm larvae plasma and Limulus amebocyte lysate methods . Nephron1997; 75: 438—443.
126.
Netea MG, Ferwerda G., de Jong DJ et al. Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J Immunol2005; 174: 6518—6523.
127.
Vermeulen MW, David JR, Remold HGDifferential mRNA responses in human macrophages activated by interferon-gamma and muramyl dipeptide. J Immunol1987; 139: 7—9.
128.
Daemen T., Veninga A., Roerdink FH, Scherphof GLIn vitro activation of rat liver macrophages to tumoricidal activity by free or liposome-encapsulated muramyl dipeptide. Cancer Res1986; 46: 4330—4335.
129.
Beutler E. , Gelbart T., West C.Synergy between TLR2 and TLR4: a safety mechanism . Blood Cells Mol Dis2001; 27: 728—730.
130.
Langhans W. , Balkowski G., Savoldelli D.Differential feeding responses to bacterial lipopolysaccharide and muramyl dipeptide. Am J Physiol1991; 261: R659—664.
131.
Flak TA, Heiss LN, Engle JT, Goldman WESynergistic epithelial responses to endotoxin and a naturally occurring muramyl peptide. Infect Immun2000; 68: 1235—1242.
132.
Uehara A., Yang S., Fujimoto Y. et al. Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture. Cell Microbiol2005; 7::53—61.
133.
Schröder NW , Morath S., Alexander C. et al. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP) and CD14 while TLR-4 and MD-2 are not involved. J Biol Chem2003; 278: 15587—15594.
134.
Kengatharan KM, De Kimpe S., Robson C., Foster SJ, Thiemermann C.Mechanism of Gram-positive shock: identification of peptidoglycan and lipoteichoic acid moieties essential in the induction of nitric oxide synthase, shock, and multiple organ failure. J Exp Med1998; 188::305—315.
135.
van Heel DA , Ghosh S., Butler M. et al. Muramyl dipeptide and Toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet2005; 365: 1794—1796.
136.
Masek K., Petrovicky P.Morphological and pharmacological evidence for the existence of brain regulatory circuits in the immune response. Int J Immunopharmacol1997; 19: 507—510.
137.
Silverman DH, Wu H., Karnovsky MLMuramyl peptides and serotonin interact at specific binding sites on macrophages and enhance superoxide release. Biochem Biophys Res Commun1985; 131: 1160—1167.
138.
Sevcik J., Masek K.The interaction of immunomodulatory muramyl dipeptide with peripheral 5-HT receptors: overview of the current state. Int J Immunopharmacol1999; 21: 227—232.
139.
Sevcik J., Ruzicka V., Slansky J., Masek K.MDP and 5-HT receptors. Does MDP interact with 5-HT(7) receptors? Int J Immunopharmacol2000; 22: 587—595.
140.
Sevcik J., Ruicka V., Slainsky J., Masek K.Muramyl dipeptide (MDP) and 5-HT receptors. Neuroimmunomodulatory effects of MDP are probably not mediated through 5-HT4 or 5-HT 1A receptors. Immunopharmacol Immunotoxicol2002; 24: 43—53.
141.
Muhvic, D. , El-Samalouti V., Flad HD, Radosevic-Stasic B., Rukavina D.The involvement of CD14 in the activation of human monocytes by peptidoglycan monomers. Mediators Inflamm2001; 10::155—162.
142.
Weidemann B., Schletter J., Dziarski R. et al. Specific binding of soluble peptidoglycan and muramyldipeptide to CD14 on human monocytes. Infect Immun1997; 65: 858—864.
143.
Asai Y., Ohyama Y., Gen K., Ogawa T.Bacterial fimbriae and their peptides activate human gingival epithelial cells through Toll-like receptor 2. Infect Immun2001; 69: 7387—7395.
144.
Hatakeyama J., Tamai R., Sugiyama A., Akashi S., Sugawara S., Takada H.Contrasting responses of human gingival and periodontal ligament fibroblasts to bacterial cell-surface components through the CD14/Toll-like receptor system. Oral Microbiol Immunol2003; 18: 14—23.
145.
Vidal VF, Casteran N., Riendeau CJ et al. Macrophage stimulation with Murabutide, an HIV-suppressive muramyl peptide derivative, selectively activates extracellular signal-regulated kinases 1 and 2, C/EBPbeta and STAT1: role of CD14 and Toll-like receptors 2 and 4 . Eur J Immunol2001; 31: 1962—1971.
146.
Dziarski R. , Tapping RI, Tobias PSBinding of bacterial peptidoglycan to CD14 . J Biol Chem1998; 273: 8680—8690.
147.
Yoshimura A., Takada H., Kaneko T., Kato I., Golenbock D., Hara Y.Structural requirements of muramylpeptides for induction of Toll-like receptor 2-mediated NF-kappaB activation in CHO cells. J Endotoxin Res2000; 6: 407—410.
148.
Morr M., Takeuchi O., Akira S., Simon MM, Muhlradt PFDifferential recognition of structural details of bacterial lipopeptides by Toll-like receptors. Eur J Immunol2002; 32: 3337—3347.
149.
Buwitt-Beckmann U., Heine H., Wiesmuller KH et al. Toll-like receptor 6-independent signaling by diacylated lipopeptides. Eur J Immunol2005; 35::282—289.
150.
Inohara N., Ogura Y., Fontalba A. et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem2003; 278: 5509—5512.
151.
Staskawicz BJ , Mudgett MB, Dangl JL, Galan JECommon and contrasting themes of plant and animal diseases. Science2001; 292::2285—2289.
152.
Inohara N., Ogura Y., Chen FF, Muto A, Nunez G. Human Nod1 confers responsiveness to bacterial lipopolysaccharides. J Biol Chem2001; 276::2551—2554.
153.
Girardin SE, Boneca IG, Carneiro LA et al. Nod1 detects a unique muropeptide from Gram-negative bacterial peptidoglycan. Science2003; 300: 1584—1587.
154.
Bertin J., Nir WJ, Fischer CM et al. Human CARD4 protein is a novel CED-4/Apaf-1 cell death family member that activates NF-kappaB. J Biol Chem1999; 274: 12955—12958.
155.
Inohara N. , Koseki T., del Peso L. et al. Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB. J Biol Chem1999 ; 274: 14560—14567.
156.
Carneiro LA , Travassos LH, Philpott DJInnate immune recognition of microbes through Nod1 and Nod2: implications for disease. Microbes Infect2004; 6: 609—616.
157.
Girardin SE , Travassos LH, Herve M. et al. Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J Biol Chem2003; 278: 41702—41708.
158.
Gutierrez O., Pipaon C., Inohara N. et al. Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factorkappa B activation. J Biol Chem2002; 277: 41701—41705.
159.
Ogura Y., Lala S., Xin W. et al. Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut2003; 52: 1591—1597.
160.
Lala S., Ogura Y., Osborne C. et al. Crohn's disease and the NOD2 gene: a role for Paneth cells. Gastroenterology2003; 125: 47—57.
161.
Abreu MT, Fukata M., Arditi M.TLR signaling in the gut in health and disease. J Immunol2005; 174::4453—4460.
162.
Berrebi D. , Maudinas R., Hugot JP et al. Card15 gene overexpression in mononuclear and epithelial cells of the inflamed Crohn's disease colon. Gut2003; 52::840—846.
163.
Maeda S., Hsu LC, Liu H. et al. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science2005; 307::734—738.
164.
Ogura Y., Bonen DK, Inohara N. et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature2001; 411::603—606.
165.
Hugot JP, Chamaillard M., Zouali H. et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature2001; 411: 599—603.
166.
Li J., Moran T., Swanson E. et al. Regulation of IL-8 and IL-1 beta expression in Crohn's disease associated NOD2/CARD15 mutations. Hum Mol Genet2004; 13: 1715—1725.
167.
Girardin SE , Hugot JP, Sansonetti PJLessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing. Trends Immunol2003; 24: 652—658.
168.
Watanabe T. , Kitani A., Murray PJ, Strober W.NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol2004; 5: 800—808.
169.
Netea MG, Kullberg BJ, de Jong DJ et al. NOD2 mediates antiinflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol2004; 34: 2052—2059.
170.
Cossart P. , Sansonetti PJBacterial invasion: the paradigms of enteroinvasive pathogens. Science2004; 304::242—248.
171.
Girardin SE , Tournebize R., Mavris M. et al. CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella flexneri. EMBO Report2001; 2: 736—742.
172.
Opitz B., Puschel A., Schmeck B. et al. Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae. J Biol Chem2004; 279: 36426—36432.
173.
Hisamatsu T., Suzuki M., Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DKCARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology2003; 124: 993—1000.
174.
Kim JG, Lee SJ, Kagnoff MFNod1 is an essential signal transducer in intestinal epithelial cells infected with bacteria that avoid recognition by Toll-like receptors. Infect Immun2004; 72: 1487—1495.
175.
Viala J., Chaput C., Boneca IG et al. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol2004; 5: 1166—1174.
